Search Results

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Phase 3 RATIONALE 315 study met its dual primary endpoints of major pathological response (MPR) by Blinded Independent Pathology Review (BIPR) and event-free survival (EFS) by Blinded Independent Central Review (BICR).

Sorrento Therapeutics, Inc. (OTC: SRNEQ) announced today the full enrollment in a pivotal Phase 3 study of Sorrento’s oral Mpro inhibitor, Ovydso (STI-1558), in mild or moderate symptomatic adults infected with SARS-CoV-2, or COVID-19.

Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its first quarter 2024 financial results on Thursday, May 2, after market close.

Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) announced today positive topline results of a pivotal Phase 3 study of Sorrento’s oral Mpro inhibitor, Ovydso (Olgotrelvir, STI-1558), in mild or moderate symptomatic adults infected with SARS-CoV-2, or COVID-19, irrespective of risk factors for severe complications.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the completion of a Phase 1 study of its oral main viral protease (Mpro) inhibitor, the STI-1558 in 58 healthy volunteers.

fast-progressing multiple myeloma patients of 65 years and older that won’t undergo a stem cell transplantation live 42 months longer when treated with the option of an MPR-R regime.